Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Beyond anti-PCSK9 therapies: the potential role of resistin inhibitors.

× No keyword cloud information.

9 in total

1. Dyslipidaemia: PCSK9 antibodies: a dividend of the genomics revolution.

Authors: Michael H Davidson
Journal: Nat Rev Cardiol Date: 2013-09-10 Impact factor: 32.419

2. The self-inhibited structure of full-length PCSK9 at 1.9 A reveals structural homology with resistin within the C-terminal domain.

Authors: Eric N Hampton; Mark W Knuth; Jun Li; Jennifer L Harris; Scott A Lesley; Glen Spraggon
Journal: Proc Natl Acad Sci U S A Date: 2007-09-05 Impact factor: 11.205

3. Effect of a monoclonal antibody to PCSK9 on LDL cholesterol.

Authors: Evan A Stein; Scott Mellis; George D Yancopoulos; Neil Stahl; Douglas Logan; William B Smith; Eleanor Lisbon; Maria Gutierrez; Cheryle Webb; Richard Wu; Yunling Du; Therese Kranz; Evelyn Gasparino; Gary D Swergold
Journal: N Engl J Med Date: 2012-03-22 Impact factor: 91.245

4. Discovery of a new role of human resistin in hepatocyte low-density lipoprotein receptor suppression mediated in part by proprotein convertase subtilisin/kexin type 9.

Authors: Michelle Melone; Larissa Wilsie; Oksana Palyha; Alison Strack; Shirya Rashid
Journal: J Am Coll Cardiol Date: 2012-05-08 Impact factor: 24.094

5. Safety and efficacy of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 serine protease, SAR236553/REGN727, in patients with primary hypercholesterolemia receiving ongoing stable atorvastatin therapy.

Authors: James M McKenney; Michael J Koren; Dean J Kereiakes; Corinne Hanotin; Anne-Catherine Ferrand; Evan A Stein
Journal: J Am Coll Cardiol Date: 2012-03-28 Impact factor: 24.094

Review 6. Resistin: functional roles and therapeutic considerations for cardiovascular disease.

Authors: Md S Jamaluddin; Sarah M Weakley; Qizhi Yao; Changyi Chen
Journal: Br J Pharmacol Date: 2012-02 Impact factor: 8.739

7. Low-density lipoprotein cholesterol-lowering effects of AMG 145, a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 serine protease in patients with heterozygous familial hypercholesterolemia: the Reduction of LDL-C with PCSK9 Inhibition in Heterozygous Familial Hypercholesterolemia Disorder (RUTHERFORD) randomized trial.

Authors: Frederick Raal; Rob Scott; Ransi Somaratne; Ian Bridges; Gang Li; Scott M Wasserman; Evan A Stein
Journal: Circulation Date: 2012-11-05 Impact factor: 29.690

8. Effect of a monoclonal antibody to PCSK9 on low-density lipoprotein cholesterol levels in statin-intolerant patients: the GAUSS randomized trial.

Authors: David Sullivan; Anders G Olsson; Rob Scott; Jae B Kim; Allen Xue; Val Gebski; Scott M Wasserman; Evan A Stein
Journal: JAMA Date: 2012-12-19 Impact factor: 56.272

9. Atorvastatin with or without an antibody to PCSK9 in primary hypercholesterolemia.

Authors: Eli M Roth; James M McKenney; Corinne Hanotin; Gaelle Asset; Evan A Stein
Journal: N Engl J Med Date: 2012-10-31 Impact factor: 91.245

9 in total

3 in total

Review 1. Vision from next generation sequencing: multi-dimensional genome-wide analysis for producing gene regulatory networks underlying retinal development, aging and disease.

Authors: Hyun-Jin Yang; Rinki Ratnapriya; Tiziana Cogliati; Jung-Woong Kim; Anand Swaroop
Journal: Prog Retin Eye Res Date: 2015-02-07 Impact factor: 21.198

2. Diabetic cardiomyopathy: is resistin a culprit?

Authors: Djamel Lebeche
Journal: Cardiovasc Diagn Ther Date: 2015-10

3. The discovery of PCSK9 inhibitors: A tale of creativity and multifaceted translational research.

Authors: Ahmed Elguindy; Magdi H Yacoub
Journal: Glob Cardiol Sci Pract Date: 2013-12-30

3 in total